Your session is about to expire
← Back to Search
Magrolimab Combinations for Multiple Myeloma
Study Summary
This trial is studying magrolimab in combination with other drugs as a possible treatment for relapsed/refractory multiple myeloma. The goal is to see if it is safe and to find out what the best dose is. Another goal is to see if it is effective in treating relapsed/refractory multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 1 & 2 trial • 78 Patients • NCT02953782Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use birth control as required by the study.My condition involves a single bone or soft tissue tumor from plasma cells.I have no active cancer except for certain skin cancers or localized prostate cancer.I have been diagnosed with Waldenstrom's macroglobulinemia.My blood has a high number of plasma cells.Your disease must be measurable using specific tests for certain proteins in your blood or urine.You are expected to live for at least 3 more months.I do not have severe nerve pain, bleeding disorders, advanced liver disease, or brain disease.I am able to get out of my bed or chair and move around.I do not have active hepatitis B or C, or HIV.I have not taken antibiotics or antiviral drugs for an infection in the last 14 days.I had a stem cell transplant using my own cells less than 100 days ago.My kidney function is within the required range.I have not had recent major surgery or cancer treatments.I had a stem cell transplant less than 6 months ago or need medicine for graft-versus-host disease.I have been diagnosed with amyloidosis, possibly related to myeloma.I have been diagnosed with multiple myeloma and need treatment.I have been diagnosed with myelodysplastic syndrome.My blood counts are within a healthy range.My condition is multiple myeloma of the IgM subtype.You are pregnant or breastfeeding.I am eligible for treatment with magrolimab and other specific drugs.I have been treated with drugs targeting CD47 or SIRPα.I have not taken glucocorticoid medications in the last 14 days.I have been diagnosed with POEMS syndrome.Your corrected serum calcium level is less than 2.9 mmol/L.My liver is working well, according to recent tests.
- Group 1: Safety Run-in Cohort (Magrolimab+Pomalidomide+Dexamethasone)
- Group 2: Safety Run-in Cohort (Magrolimab+Bortezomib+Dexamethasone)
- Group 3: Safety Run-in Cohort (Magrolimab+Daratumumab)
- Group 4: Safety Run-in Cohort (Magrolimab+Carfilzomib+Dexamethasone)
- Group 5: Dose Expansion Cohort (Magrolimab+Daratumumab)
- Group 6: Dose Expansion Cohort (Magrolimab+Pomalidomide+Dexamethasone)
- Group 7: Dose Expansion Cohort (Magrolimab+Carfilzomib+Dexamethasone)
- Group 8: Dose Expansion Cohort (Magrolimab+Bortezomib+Dexamethasone)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Magrolimab received official sanction from the FDA?
"Our assessment of Magrolimab's safety levels is 2, which indicates that while some data exists to support its safety profile, there are currently no studies demonstrating the efficacy."
What maladies has Magrolimab been proven to alleviate?
"Magrolimab is a medication that effectively and reliably treats ophthalmia, sympathetic as well as branch retinal vein occlusion, macular edema, and communicable diseases."
Are there any opportunities for enrolment in this trial yet?
"Data hosted on clinicaltrials.gov reveals that this research endeavour, initially posted on November 9th 2021 and recently modified on November 10th 2022, is currently searching for participants."
What precedent has been established with regards to Magrolimab research?
"Currently, there are 673 active clinical studies relating to Magrolimab with 153 of those trials in their third and final stage. Of these trials, a majority are being conducted at sites located in Joliet, Illinois; however worldwide the total number of trial locations comes out to 21897."
In what geographical areas is this research trial being conducted?
"This study is taking place at 12 locations, including Oregon Health and Science University in Portland, Arizona Oncology Associates , PC - HOPE in Tucson, and Roswell Park Cancer Institute in Buffalo. Additionally, there are 9 other sites where patients can receive the medication."
Share this study with friends
Copy Link
Messenger